Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B

Table 3 Multivariate analysis for risk factors of virologic breakthrough

	HR	95%CI	P value1
HBeAg (+)	3.251	0.400-26.403	0.270
Albumin (g/dL)	0.552	0.194-1.573	0.266
ALP (IU/L)	1.004	0.994-1.014	0.427
PT (INR)	1.269	0.186-8.648	0.808
Platelet (× 103/mm3)	0.997	0.986-1.007	0.519
Cirrhosis	1.016	0.243-4.448	0.983
Duration of prior lamivudine treatment (mo)	0.99	0.945-1.038	0.691
Inadequate response2	6.57	–1.517-28.458	0.012
Treatment groups3			0.029
Group B vs group A	0.668	0.149-2.984	0.597
Group C vs group A	0.096	0.015-0.629	0.015

¹P-values were calculated with Cox’s proportional hazard model; Variables with a P < 0.1 in the univariate analysis were included in the multivariate analysis;

²Inadequate response was defined as serum HBV DNA levels of 2000 IU/mL or greater at 6 mo of treatment;

³Treatment groups were divided into three groups according to the timing of the drug combination; groups A and B represent the patients who followed or violated the roadmap treatment strategy, respectively; group C included those participants who were treated by adding adefovir dipivoxil (adefovir) to ongoing lamivudine therapy. Roadmap treatment strategy was supposed to initiate adefovir monotherapy first and then add lamivudine later when serum HBV DNA levels were detectable (≥ 60 IU/mL) at six months of treatment. HBeAg: Hepatitis B e antigen; ALP: Alkaline phosphatase; PT: Prothrombin time; INR: International normalized ratio; HR: Hazard ratio.